Thermo Fisher Scientific Inc. $TMO Shares Sold by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,086,025 shares of the medical research company's stock after selling 92,094 shares during the period. Thermo Fisher Scientific makes up about 0.8% of Mitsubishi UFJ Asset Management Co. Ltd.'s portfolio, making the stock its 16th largest holding. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.56% of Thermo Fisher Scientific worth $1,235,991,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $28,000. Beacon Financial Strategies CORP purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Olistico Wealth LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $29,000. Cloud Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $38,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.9%

Thermo Fisher Scientific stock opened at $466.74 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a 50 day moving average price of $495.23 and a 200 day moving average price of $547.61. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a market capitalization of $173.45 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 2.05 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company's quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's payout ratio is currently 10.34%.

Analyst Ratings Changes

A number of analysts have recently issued reports on TMO shares. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 14th. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 target price for the company. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $623.05.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company's stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,800 shares of company stock worth $2,963,544 in the last three months. Corporate insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.